Airline stocks were suffering a broad selloff ahead of Monday's open, amid a big drop in the broader stock market and as a surge of the delta variant of the coronavirus that causes COVID-19 increases fears of potential travel restrictions. The U.S. Global Jets ETF
JETS,
Pfizer Inc. undefined said Friday that the Food and Drug Administration accepted its application for full approval of the COVID-19 vaccine it developed with BioNTech SE undefined. As part of the application process, the FDA sets a decision date based on the rules of the Prescription Drug User Fee Act for applications that receive what is called Priority Review. The decision date is set for an undisclosed day in January, Pfizer said. This means that Pfizer's COVID-19 shot may not be fully approved in the U.S. until then, though the decision could occur sooner. Pfizer's shot was first authorized as part of emergency rules back in December 2020. Since then, more than 207 million doses of this vaccine have been administered to people in the U.S. Pfizer's stock is up 9.6% so far this year, while the broader S&P 500 undefined is up 15.2%.